OncoMatch/Clinical Trials/NCT04701476
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Is NCT04701476 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including TATE and pembrolizumab and TAS-102 pill for colorectal cancer; lung cancer.
Treatment: TATE and pembrolizumab · TAS-102 pill · Regorafenib Pill — Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Non-Small Cell Lung Carcinoma
Colorectal Cancer
Biomarker criteria
Required: EGFR wild-type
NSCLC without EGFR or AKT mutations
Required: AKT1 wild-type
NSCLC without EGFR or AKT mutations
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
mCRC progressed on at least two lines of standard chemotherapy
Must have received: chemotherapy
NSCLC progressed on chemotherapy
Must have received: checkpoint inhibitor
NSCLC progressed on ... an immune checkpoint inhibitor
Cannot have received: organ transplantation
Prior organ transplantation
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, Irvine Medical Center · Orange, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04701476 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior organ transplantation disqualifies patients from enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require AKT1?
Yes, AKT1 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify